MedTrace Logo

Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

NCT05435053 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-09-15

No results posted yet for this study

Summary

The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.

Conditions

  • Pancreas Cancer

Interventions

DRUG

Nivolumab

Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor).

DEVICE

Irreversible electroporation (IRE)

Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion. Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use.

Sponsors & Collaborators

  • Ismail Gögenur

    lead OTHER

Principal Investigators

  • Ismail Gögenur, Professor · Zealand University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-08
Primary Completion
2023-08-30
Completion
2023-08-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435053 on ClinicalTrials.gov